BioMarin achieved strong topline growth in Q4 2025 with total revenues increasing 17% year-over-year, driven by robust performance in VOXZOGO and Enzyme Therapies. However, the company reported a GAAP net loss for the quarter primarily due to $240 million in charges related to the strategic decision to voluntarily withdraw ROCTAVIAN from the market.

BioMarin delivered 4% revenue growth in Q3 2025 led by VOXZOGO and PALYNZIQ. However, GAAP net loss widened due to a $221M IPR&D expense. The company reaffirmed guidance for VOXZOGO and announced plans to divest ROCTAVIAN.

BioMarin delivered a strong second quarter in 2025, with total revenues reaching $825 million, a 16% increase year-over-year, driven by robust growth in VOXZOGO and Enzyme Therapies. The company also saw significant profitability expansion, with GAAP net income increasing by 125% to $241 million and non-GAAP income growing by 49% to $282 million. BioMarin raised its full-year 2025 guidance for key financial metrics, reflecting continued patient demand and operational efficiencies.

BioMarin delivered a solid Q1 2025 performance, with revenue up 15% and net income more than doubling year-over-year. VOXZOGO saw strong global demand, and the company benefited from operational efficiency following its 2024 strategic review.

BioMarin achieved $747 million in total revenue for Q4 2024, a 16% year-over-year increase, driven by strong contributions from VOXZOGO and enzyme therapies. GAAP net income reached $125 million, up significantly from the prior year, while non-GAAP income grew to $180 million. The company also reported continued operational efficiency improvements and expects sustained growth in 2025.

BioMarin announced strong Q3 2024 results, with a 28% increase in total revenue to $746 million, driven by VOXZOGO and Enzyme Therapies. The company raised its full-year 2024 guidance and reaffirmed its long-term outlook, reflecting confidence in its growth strategy and operational efficiency.

BioMarin announced a 20% year-over-year increase in total revenue for the second quarter of 2024, reaching $712 million. Strong VOXZOGO demand and growth from enzyme therapies drove the increase. The company raised its full-year 2024 guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.

BioMarin reported a 9% year-over-year increase in total revenues, reaching $649 million for Q1 2024. GAAP diluted EPS increased by 70% to $0.46, and non-GAAP diluted EPS increased by 18% to $0.71. The company reaffirmed its full-year 2024 total revenue guidance and raised its non-GAAP operating margin and non-GAAP EPS guidance.

BioMarin reported strong financial results for Q4 2023, driven by global demand for VOXZOGO and contributions from established enzyme products. Total revenues increased by 20% compared to the same period in 2022, with VOXZOGO revenues growing by 118%. The company's 2024 financial outlook reflects anticipated double-digit total revenue growth and significant Non-GAAP operating margin expansion.

BioMarin announced strong third quarter 2023 results, including continued profitability, and 15% total revenue growth year over year. Total revenues for the third quarter of 2023 were $581.3 million, an increase of 15% compared to the same period in 2022.

BioMarin Pharmaceutical Inc. announced strong second quarter 2023 results with total revenues of $595.3 million, a 12% increase compared to the same period in 2022. The company reached more children with VOXZOGO and received U.S. approval of ROCTAVIAN. BioMarin is focused on expanding VOXZOGO globally and treating the first ROCTAVIAN patients in the U.S. and Europe.

BioMarin announced strong Q1 2023 results, driven by VOXZOGO's global uptake and solid enzyme business growth. Total revenues increased by 15% year-over-year to $596.4 million, while GAAP Net Income decreased to $50.9 million, and Non-GAAP Income increased to $115.8 million.

BioMarin announced strong Q4 and full-year 2022 results, driven by VOXZOGO's global launch and enzyme business growth. Total revenues for Q4 2022 were $537.5 million, a 19% increase compared to 2021. The company is focusing on the European commercial launch of ROCTAVIAN and preparing for its potential U.S. approval.

BioMarin announced strong Q3 2022 results, with a 24% increase in total revenue compared to the same period in 2021. VOXZOGO's performance was a key driver, leading to an increased full-year net product revenue guidance. The company also highlighted the European regulatory approval and commercial launch of ROCTAVIAN, as well as the acceptance of the U.S. Biologics Application for ROCTAVIAN by the FDA.

BioMarin announced record revenues in the second quarter of 2022, driven by strong growth of VOXZOGO and solid contributions from other franchises. Total revenues reached $533.8 million, a 6% increase compared to the same period in 2021. The company increased its full-year 2022 top and bottom-line guidance.

BioMarin announced record total revenues of $519 million for Q1 2022, driven by VOXZOGO and growth in Vimizim and Naglazyme revenues. GAAP Net Income increased to $120.8 million compared to $17.4 million for the same period in 2021. The company increased full-year 2022 financial guidance for Voxzogo net product revenues.

BioMarin Pharmaceutical Inc. announced its Q4 and full-year 2021 financial results, with total revenues for the fourth quarter of 2021 were $449.8 million, essentially flat compared to the same period in 2020. The company is focusing on the launch of Voxzogo and the potential approval of valoctocogene roxaparvovec to drive growth in 2022.

BioMarin's Q3 2021 total revenues decreased to $408.7 million compared to $476.8 million for the same period in 2020. GAAP net loss increased to $36.5 million, while non-GAAP net income decreased to $33.5 million.

BioMarin announced strong Q2 2021 financial results, with total revenues increasing by 17% compared to Q2 2020. The company is raising its full-year 2021 financial guidance and has achieved key regulatory milestones, including a positive CHMP opinion for VOXZOGO in Europe and validation of its MAA for valoctocogene roxaparvovec.

BioMarin announced its Q1 2021 financial results, with total revenues decreasing by 3% compared to Q1 2020, primarily due to lower Kuvan sales. However, Vimizim and Palynziq revenues increased. The company reaffirmed its full-year 2021 financial guidance and anticipates regulatory decisions for vosoritide and valoctocogene roxaparvovec in Europe.

BioMarin announced its Q4 2020 financial results, with total revenues of $452.1 million. The company's full-year revenues reached $1.86 billion, a 9% increase year-over-year. Key pipeline updates included positive Phase 3 results for valoctocogene roxaparvovec in severe hemophilia A and sustained growth effects for vosoritide in children with achondroplasia.

BioMarin announced financial results for Q3 2020, with total revenues of $477 million. GAAP Net Income was $784.8 million, and Non-GAAP Income was $98.7 million. The company is working with health authorities regarding valoctocogene roxaparvovec and anticipates sharing Phase 3 study results in Q1 2021.

BioMarin announced its second quarter 2020 financial results, with total revenue growth of 11% to $430 million. The company is progressing with regulatory submissions for Valoctocogene Roxaparvovec and Vosoritide and anticipates GAAP profitability for the full year 2020.

BioMarin announced a 25% increase in total revenue, reaching $502.1 million in the first quarter of 2020. The company experienced growth across its product portfolio, notably Naglazyme, Palynziq, Kuvan and Brineura. GAAP net income was $81.4 million, a significant improvement from the previous year's net loss. The company is reducing full year revenue guidance by 5% due to COVID-19 impacts.

BioMarin announced a 29% increase in total revenues for Q4 2019, reaching $454.4 million compared to $353.2 million in Q4 2018. The growth was primarily driven by increased net product revenues, particularly from Palynziq, Vimizim, Naglazyme, and Brineura. The company also reported a GAAP net income of $15.0 million for the quarter, a significant improvement from the net loss of $3.7 million in the same period of the previous year.